These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 2743709

  • 41. Alfentanil clearance is independent of the polymorphic debrisoquin hydroxylase.
    Henthorn TK, Avram MJ, Krejcie TC.
    Anesthesiology; 1989 Nov; 71(5):635-9. PubMed ID: 2817455
    [Abstract] [Full Text] [Related]

  • 42. Stereoselective disposition of racemic E-10-hydroxynortriptyline in human beings.
    Dahl-Puustinen ML, Perry TL, Dumont E, von Bahr C, Nordin C, Bertilsson L.
    Clin Pharmacol Ther; 1989 Jun; 45(6):650-6. PubMed ID: 2731406
    [Abstract] [Full Text] [Related]

  • 43. Nortriptyline and debrisoquine hydroxylations in Ghanaian and Swedish subjects.
    Woolhouse NM, Adjepon-Yamoah KK, Mellström B, Hedman A, Bertilsson L, Sjöqvist F.
    Clin Pharmacol Ther; 1984 Sep; 36(3):374-8. PubMed ID: 6467797
    [Abstract] [Full Text] [Related]

  • 44. Inhibition of desipramine 2-hydroxylation by quinidine and quinine.
    Steiner E, Dumont E, Spina E, Dahlqvist R.
    Clin Pharmacol Ther; 1988 May; 43(5):577-81. PubMed ID: 3365919
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. [Hydroxylation of debrisoquin in Parkinson's disease].
    Meillard MN, Bentué-Ferrer D, Brunet-Bourgin F, Morel G, Allain H.
    Presse Med; 1990 May 19; 19(20):947-9. PubMed ID: 2141131
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Low frequency of slow debrisoquine hydroxylation in a native Chinese population.
    Lou YC, Ying L, Bertilsson L, Sjöqvist F.
    Lancet; 1987 Oct 10; 2(8563):852-3. PubMed ID: 2889047
    [No Abstract] [Full Text] [Related]

  • 53. Metabolism of methoxyphenamine in extensive and poor metabolizers of debrisoquin.
    Roy SD, Hawes EM, McKay G, Korchinski ED, Midha KK.
    Clin Pharmacol Ther; 1985 Aug 10; 38(2):128-33. PubMed ID: 4017414
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Ifosfamide plasma clearance in relation to polymorphic debrisoquine oxidation.
    Philip PA, Lewis LD, James CA, Rogers HJ.
    Cancer Chemother Pharmacol; 1988 Aug 10; 22(4):321-4. PubMed ID: 3168145
    [Abstract] [Full Text] [Related]

  • 59. Slow hydroxylation of tricyclic antidepressants--relationship to polymorphic drug oxidation.
    Sjöqvist F, Bertilsson L.
    Prog Clin Biol Res; 1986 Aug 10; 214():169-88. PubMed ID: 3523507
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.